|
|
|
Russian Pharma Industry In Details
5/9/2013 | published by: Euroresearch & Consulting
Russian Pharma Industry In Details
Purpose of this report was to analyze Russian of pharma.
Please pay attention:
Benefits of buying the report:
The report included large volume
|
read more...
|
$3,750.00
|
|
Australia Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceuticalinvestors, given its ageing and generally affluent population. Importantly, the government is implementingcost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers
|
read more...
|
$1,175.00
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2013
5/8/2013 | published by: Business Monitor International
BMI View: While the patent cliff and the consequent availability of generic drugs, as well as price cuts ongeneric medicines and their increasing affordability, will work towards increasing the consumption ofgeneric medicines in Switzerland, BMI
|
read more...
|
$1,175.00
|
|
Chile Pharmaceuticals and Healthcare Report Q2 2013
5/1/2013 | published by: Business Monitor International
BMI View: Chile's improving regulation system should bring high quality medicines to the local marketand eventually reduce the country's medical spending. The tightened bioequivalent regulations will boostgenuine medicine sales and force similares out of the
|
read more...
|
$1,175.00
|
|
Central America Pharmaceuticals and Healthcare Report Q3 2013
5/1/2013 | published by: Business Monitor International
BMI View: Commercial incentives for foreign drugmakers to expand in the Central Americanpharmaceutical market are limited by the region's relatively low per capita pharmaceutical spending andmarket growth. However, the heavy reliance on imported medicine in
|
read more...
|
$1,175.00
|
|
Qatar Pharmaceuticals and Healthcare Report Q2 2013
5/1/2013 | published by: Business Monitor International
BMI View: Qatar represents a largely risk-free proposition for multinational drug manufacturers,although the potential returns are modest, on the account of a small overall market size. Additionally,despite the authorities' desire to increase the domestic medicine
|
read more...
|
$1,175.00
|
|
China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi
5/20/2013 | published by: Access China Management Consulting Ltd.
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of traditional Chinese medicines almost can not been expressed by
|
read more...
|
$750.00
|
|
Cameroon Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: Despite the strong growth potential of its pharmaceutical market, we believe Cameroon isunlikely to be of significant interest to multinational pharmaceutical firms. The country's shortcomingsinclude poor public health provision and rampant corruption. Consequently
|
read more...
|
$1,175.00
|
|
Namibia Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: We expect Namibia's negative pharmaceutical trade balance to widen as demand for medicinescontinues to be met by imports, and poor local manufacturing sees exports contract in the medium term.Headline Expenditure Forecasts Pharmaceuticals: NAD2.20bn
|
read more...
|
$1,175.00
|
|
Cote d'Ivoire Pharmaceuticals and Healthcare Report Q3 2013
5/15/2013 | published by: Business Monitor International
BMI View: The risks of investing in Côte d'Ivoire's pharmaceutical and healthcare industry arenumerous. Politically, the country is in a fragile state, with concerns over security commonplace.Economically, Côte d'Ivoire posts a better performance, but there
|
read more...
|
$1,295.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Country Overviews Reports